drugset / Trial / NCT02700360

Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers

NCT02700360 ↗

Phase 1 Completed 36 enrolled Enzychem Lifesciences Corporation
RandomizedCrossoverOpen-label

Summary

A Randomized, Open-Label, Single -Dose, Crossover, Phase I Clinical Trial to Evaluate the Effect of Food on the Safety, Tolerability and Pharmacokinetics of EC-18 after Oral Administration in Healthy Volunteers

Timeline

Start
2015-08
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject MOSEDIPIMOD Small molecule 500 mg Oral
Subject MOSEDIPIMOD Small molecule 1000 mg Oral
Subject MOSEDIPIMOD Small molecule 2000 mg Oral

Indications